|
Diagnostic Tool for High-grade Serous Ovarian Cancer - (HJF 616-21)
Researchers at HJF, Inova Fairfax Hospital (IFH), and the Peter MacCallum Cancer Center (PMCC) have identified orthogonal protein and transcript-based biomarkers correlating with Homologous Recombination Deficiency (HRD). This may lead to a companion clinical diagnostic assay to prioritize High-Grade Serous Ovarian Cancer (HGSOC) patients for targeted...
Published: 12/12/2024
|
Updated: 12/12/2024
|
Inventor(s): Nicholas Bateman, Tamara Abulez, Thomas Conrads, George Larry Maxwell, Dale Garsed, David Bowtell, Ahwan Pandey
Keywords(s): Assay, Biomarker Assay, Companion Diagnostic, DDR, DNA Damage Repair, HGSOC, High-Grade Serous Ovarian Carcinoma, Ovarian Cancer, PARP Inhibitors
Category(s): Diagnostics, Therapeutic
|
|
Immunogens and Vaccine Compositions Against Flavivirus - (HJF 624-22)
HJF researchers have developed a novel recombinant flavivirus immunogen that can induce immunogenicity against multiple flaviviruses, including ZIKV (Zika) and DENV (dengue), without life-threatening antibody-dependent enhancement (ADE) responses. Mice immunized with this recombinant immunogen were protected from lethal ZIKV challenge.
Applications...
Published: 12/12/2024
|
Updated: 12/1/2023
|
Inventor(s): Shelly Krebs, Vincent Dussupt
Keywords(s): Dengue, Flavivirus, Immunogen, Vaccines, Zika
Category(s): Diagnostics, Therapeutic
|
|
DNA Damage Repair Genes in Prostate Cancer - (HJF 557-19)
Prostate cancer patients with DDRG mutations are increasingly considered for targeted cancer therapies. Currently available DDRG mutation tests rely on a rather small number of genes which are not often mutated in African American prostate cancer patients. This invention describes a robust data set on inherited mutations which can be used to develop...
Published: 5/6/2024
|
Updated: 12/1/2023
|
Inventor(s): Gyorgy Petrovics, Shiv Srivastava
Keywords(s): African American, Caucasian, DDRG, Mutation, Precision Therapy, Prostate Cancer
Category(s): Diagnostics
|
|
Predictive Tool on Probability of Successful Wound Closure - (HJF 637-22)
Greater than 20% of traumatic wound closure attempts fail due to the immuno-molecular status of the healing wound tissue.
Researchers at HJF and the Uniformed Services University for Health Sciences (USU) developed a product that analyzes the individual's wound healing immune response and computes a risk of failure score based on cytokine levels...
Published: 12/12/2024
|
Updated: 10/12/2023
|
Inventor(s): Seth Schobel-McHugh, Eric Elster, Henry Robertson, Felipe Lisboa, Michael Rouse, Scott Grey
Keywords(s): Biomarker, CDST, Dehisced Wound, Effluent, Healing, Serum, Wound, Wound Closure, Wound Failure
Category(s): Diagnostics, Medical Devices, Therapeutic, Healthcare IT
|
|
ETV1 Monoclonal Antibodies - (HJF 641-23)
ETV1 is a protein of Erythroblast Transformation Specific (ETS) family of transcription factors. Dysregulation of ETV-1 has been observed in many malignancies including, gastrointestinal stromal (GIS), prostatic tumors, and in triple-negative breast cancer.
Researchers at Henry M. Jackson Foundation (HJF) and Uniformed Services University for Health...
Published: 10/17/2024
|
Updated: 4/5/2023
|
Inventor(s): Shyh-Han Tan, Albert Dobi, Shiv Srivastava
Keywords(s): ERG, Monoclonal Antibodies, Prostate Cancer
Category(s): Diagnostics, Research Tool, Therapeutic
|
|
Vaccines Against Fentanyl and Fentanyl Analogs - (HJF 561-19)
A technology related to novel fentanyl hapten compounds and their use in the preparation of vaccines against fentanyl and fentanyl analogs is available for licensing.
Applications and Advantages
Novel compounds for use as vaccines against fentanyl and analogs
High immunogenicity that generates fentanyl specific antibodies to reduce its distribution...
Published: 10/17/2024
|
Updated: 3/27/2023
|
Inventor(s): Gary Matyas, Oscar Torres, Kenner Rice, Eric Bow, Agnieszka Sulima, Arthur Jacobson
Keywords(s): Antibody, Diagnostics, Fentanyl, Therapeutics, Vaccines
Category(s): Diagnostics, Therapeutic, Vaccine
|
|
Predicting and Addressing Severe Disease in Sepsis Patients - (HJF 517-18)
Researchers at Henry M. Jackson Foundation (HJF) have developed diagnostic tools to predict severe sepsis or the risk of developing severe sepsis prior to the onset of any measurable symptoms. As sepsis mortality is known to increase with delay in anti-microbial administration, this predictive model can give clinicians lead time to plan and execute...
Published: 10/17/2024
|
Updated: 1/27/2023
|
Inventor(s): Danielle Clark, Joost Brandsma, Deborah Striegel, Rittal Mehta
Keywords(s): Biomarker
Category(s): Diagnostics
|
|
Potent ZIKV and DENV neutralizing antibodies induced by ZPIV vaccination - (HJF 508-18)
Researchers at The Henry M. Jackson Foundation (HJF), The Beth Israel Deaconess Medical Center (BIDMC), the Armed Forces Research Institute of Medical Sciences (AFRIMS), and the Walter Reed Army Institute of Research (WRAIR) have identified several monoclonal antibodies (mAbs) with a wide-range of capabilities to precisely neutralize Zika virus (ZIKV)...
Published: 10/17/2024
|
Updated: 1/27/2023
|
Inventor(s): Shelly Krebs, Vincent Dussupt, Gina Donofrio, Kayvon Modjarrad, Nelson Michael, Dan Barouch, Michael Gordon Joyce, Kathryn Stephenson, Rajeshwer Sankhala
Keywords(s):
Category(s): Diagnostics, Therapeutic, Vaccine
|
|
Vaccines against SARS-COV-2 and other Coronaviruses - (HJF 569-20 & HJF 635-22)
Researchers at HJF and the Walter Reed Army Institute of Research (WRAIR) have developed novel vaccines comprised of fusion proteins; Ferritin nanoparticle and antigenic coronavirus peptide(s). These fusion proteins generate simultaneous protective neutralizing immune responses against coronaviruses and their variants.
Applications and Advantages
Innovation...
Published: 12/12/2024
|
Updated: 1/25/2023
|
Inventor(s): Kayvon Modjarrad, Michael Gordon Joyce
Keywords(s): Coronavirus, COVID-19, Nano-particle, SARS-CoV-2, Self-Assembly, Vaccines, Variants
Category(s): Diagnostics, Therapeutic
|
|
Protein Panels for the Early Diagnosis/Prognosis and Treatment of Aggressive Prostate Cancer - (HJF 528-18)
Prostate cancer is the second most common cancer in men and fourth most common among all cancers. Researchers at the Henry M. Jackson Foundation (HJF) in collaboration with researchers at the Pacific Northwest National Laboratory (PNNL) and the National Cancer Institute (NCI) have developed a novel protein-panel based diagnosis or prognosis method that...
Published: 5/6/2024
|
Updated: 1/24/2023
|
Inventor(s): Shiv Srivastava, Gyorgy Petrovics, Jennifer Cullen, Tao Liu, Karin Rodland
Keywords(s):
Category(s): Diagnostics, Prognostic
|